Evidence map›Paper›PMID 32798224›Full record

Trial reportThe Journal of infectious diseases2021

One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine.

Ali Faisal Saleem, Ondrej Mach, Mohammad Tahir Yousafzai, Zaubina Kazi, Attaullah Baig, Muhammad Sajid, Vishali Jeyaseelan, Roland W Sutter, Anita K M Zaidi

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03286803 phase4unknown statusnot on this map

Comparison of Immunity Following Inactivated Poliovirus Vaccine Versus Fractional Dose Inactivated Poliovirus Vaccine: a Community Based Randomized Controlled Trial in Pakistan

TypeinterventionalSponsorAga Khan UniversityRan2017 to 2019Enrolled500ConditionsPoliovirus Vaccine, Inactivated, Poliomyelitis, Immunization, InfectionArmsInactivated Poliovirus vaccine
NCT05162482 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial

TypeinterventionalSponsorAga Khan University Hospital, PakistanRan2022 to 2024Enrolled1,680ConditionsCOVID 19 VaccineArmsBIBP (CNBG, Sinopharm) WIV, CanSinoBIO, AstraZeneca ChAdOx
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Ali Faisal SaleemAga Khan University, Karachi, Pakistan.
Ondrej MachPolio Eradication Department, World Health Organization, Geneva, Switzerland.
Mohammad Tahir YousafzaiAga Khan University, Karachi, Pakistan.
Zaubina KaziAga Khan University, Karachi, Pakistan.
Attaullah BaigAga Khan University, Karachi, Pakistan.
Muhammad SajidAga Khan University, Karachi, Pakistan.
Vishali JeyaseelanPolio Eradication Department, World Health Organization, Geneva, Switzerland.
Roland W SutterPolio Eradication Department, World Health Organization, Geneva, Switzerland.
Anita K M ZaidiAga Khan University, Karachi, Pakistan.
Aga Khan University · PKWorld Health Organization · CH

Funding

Pediatric Infectious Diseases, Enteric Health and Malnutrition in Pakistan (PIDEMP) Research Training ProgramD43TW007585 · FIC · AGA KHAN UNIVERSITY (PAKISTAN) · PI ALI, SYED ASAD, MOORE, SEAN RYAN · 2006 to 2024
$3.7M
FIC NIH HHS D43 TW007585World Health Organization 001
6 · The paper itself

Abstract

backgroundFractional dose (one-fifth of full intramuscular dose) of inactivated poliovirus vaccine (fIPV) administered intradermally is used as IPV dose-sparing strategy. We compared the rate of decline of poliovirus antibodies (PVA) in recipients of 2 doses of fIPV or IPV.

methodsA community-based randomized controlled trial was conducted in Karachi, Pakistan. Children aged 14 weeks were randomized into fIPV or full IPV (study arms A, B) and received 1 vaccine dose at age 14 weeks and 1 at age 9 months. PVAs were measured at age 14, 18 weeks and 10, 21 months.

resultsSeroprevalence of poliovirus type 2 antibodies in 170/250 (68%) children after 2 IPV or fIPV doses at age 10 months in A and B reached 100% vs 99% (P = .339), and at 21 months, 86% vs 67% (P = .004). Between age 10 and 21 months antibody log2 titers dropped from ≥ 10.5 to 6.8 in A and from 9.2 to 3.7 in B.

conclusionsThere was a significant decline in antibody titers 12 months following the second IPV dose. The slope of decline was similar for full IPV and fIPV recipients. The results provide further evidence that fIPV is a viable option for IPV dose-sparing. CLINICAL TRIALS REGISTRATION: NCT03286803.

Indexed as

PoliomyelitisPoliovirusAntibodies, ViralDose-Response Relationship, ImmunologicHumansImmunization ScheduleInfantInjections, IntradermalPakistanPoliovirus Vaccine, InactivatedSeroepidemiologic StudiesAntibodies, ViralPoliovirus Vaccine, Inactivatedchildrenduration of immunityinactive polio vaccineseroprevalence

Identifiers

PMID32798224
PMCPMC8030725
OpenAlexW3049585175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.